Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.

Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC

Diabetes, obesity & metabolism21 Feb 2018Cited by 49 (Europe PMC)

PMID29377522DOI10.1111/dom.13237PepBankPUB-29377522

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In GADA-negative T2D patients, dulaglutide reduced HbA1c by 1.09% at 12 months (95% CI -1.15 to -1.03).
In plain wordsIn GADA-negative T2D patients, blood sugar improved compared with baseline during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in GADA-negative patients
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.09%
GADA-negative at 12 months
95% CI lower
−1.15%
GADA-negative
95% CI upper
−1.03%
GADA-negative
Source sentences
Summary
Dulaglutide resulted in comparable HbA1c reductions in GADA-negative (LS mean change [95%CI], -1.09% [-1.15, -1.03]) and GADA-positive patients (-0.94% [-1.15, -0.72]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
Report a problemFND-2937752201
02HumanObservational studyEfficacy outcome
In GADA-positive LADA patients, dulaglutide reduced HbA1c by 0.94% at 12 months (95% CI -1.15 to -0.72).
In plain wordsIn GADA-positive LADA patients, blood sugar improved compared with baseline during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in GADA-positive patients
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−0.94%
GADA-positive at 12 months
95% CI lower
−1.15%
GADA-positive
95% CI upper
−0.72%
GADA-positive
Source sentences
Summary
Dulaglutide resulted in comparable HbA1c reductions in GADA-negative (LS mean change [95%CI], -1.09% [-1.15, -1.03]) and GADA-positive patients (-0.94% [-1.15, -0.72]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
Report a problemFND-2937752202
03HumanObservational studyEfficacy outcome
In GADA-low patients, HbA1c fell by 1.02% with dulaglutide at 12 months (95% CI -1.26 to -0.78).
In plain wordsIn GADA-low patients, blood sugar fell compared with baseline during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in GADA-low patients
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.02%
GADA-low at 12 months
95% CI lower
−1.26%
GADA-low
95% CI upper
−0.78%
GADA-low
Source sentences
Summary
HbA1c reductions were numerically, but not statistically, significantly larger in GADA-low patients (-1.02% [-1.26, -0.78]) vs GADA-high patients (-0.72% [-1.21,-0.24]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
Report a problemFND-2937752204
04HumanObservational studyEfficacy outcome
In GADA-high patients, HbA1c fell by 0.72% with dulaglutide at 12 months (95% CI -1.21 to -0.24).
In plain wordsIn GADA-high patients, blood sugar fell compared with baseline during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change in GADA-high patients
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−0.72%
GADA-high at 12 months
95% CI lower
−1.21%
GADA-high
95% CI upper
−0.24%
GADA-high
Source sentences
Summary
HbA1c reductions were numerically, but not statistically, significantly larger in GADA-low patients (-1.02% [-1.26, -0.78]) vs GADA-high patients (-0.72% [-1.21,-0.24]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
Report a problemFND-2937752205

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, HbA1c reductions were comparable between GADA-negative and GADA-positive groups at 12 months.
In plain wordsIn dulaglutide-treated patients, blood sugar reductions were comparable between GADA-negative and GADA-positive groups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction by GADA status
Study
n: not reported in source
Comparator
GADA-positive patients
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c LS mean change
−1.09%
GADA-negative at 12 months
95% CI
−1.15 to −1.03%
GADA-negative at 12 months
HbA1c LS mean change
−0.94%
GADA-positive at 12 months
95% CI
−1.15 to −0.72%
GADA-positive at 12 months
Source sentences
Summary
Dulaglutide resulted in comparable HbA1c reductions in GADA-negative (LS mean change [95%CI], -1.09% [-1.15, -1.03]) and GADA-positive patients (-0.94% [-1.15, -0.72]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2937752203
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, HbA1c reductions were numerically larger in GADA-low than GADA-high patients, without statistical significance.
In plain wordsIn dulaglutide-treated patients, blood sugar reductions did not differ significantly between GADA-low and GADA-high patients.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction by GADA titer
Study
n: not reported in source
Comparator
GADA-high patients
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c LS mean change
−1.02%
GADA-low at 12 months
95% CI
−1.26 to −0.78%
GADA-low at 12 months
HbA1c LS mean change
−0.72%
GADA-high at 12 months
95% CI
−1.21 to −0.24%
GADA-high at 12 months
Source sentences
Summary
HbA1c reductions were numerically, but not statistically, significantly larger in GADA-low patients (-1.02% [-1.26, -0.78]) vs GADA-high patients (-0.72% [-1.21,-0.24]) at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D.
Summary · context
Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2937752206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.

Summary

Results from this study6

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords